Subscribe To
INO / INOVIO Pharmaceuticals (INO) Stock Price: Why It Rose Over 14% Today
INO News
By Proactive Investors
October 10, 2023
Inovio shares rise after positive FDA feedback on RRP treatment candidate
Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treatin more_horizontal
By Seeking Alpha
September 12, 2023
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Partici more_horizontal
By Seeking Alpha
June 28, 2023
Inovalis: Orange You Glad You Stayed Away?
We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improba more_horizontal
By Seeking Alpha
June 9, 2023
Inovio Pharmaceuticals, Inc. (INO) Jefferies Healthcare Conference 2023 (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - Preside more_horizontal
By Zacks Investment Research
May 24, 2023
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug d more_horizontal
By Seeking Alpha
May 17, 2023
Inovio Pharmaceuticals, Inc. (INO) 2023 RBC Capital Markets Global Healthcare Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Ren more_horizontal
By Zacks Investment Research
May 15, 2023
All You Need to Know About Inovio (INO) Rating Upgrade to Buy
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stoc more_horizontal
By Zacks Investment Research
May 10, 2023
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares t more_horizontal